Biologically active substances from water invertebrates: A review

Veterinarni Medicina

Volumn 57, Issue 4, 2012, Pages 177-184

  Sinko, J ^a   Rajchard, Josef ^a   Balounova, Z ^a   Fikotova, L ^a  

^a UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

Author keywords

Antipredatory effect; Bioactive substances; Bryostatin; Bryozoan; Bugula neritina; Competition; Isocyano terpenes; Marine sponges; Snails; Symbiont; Tunicates

Indexed keywords

EID: 84865331560     PISSN: 03758427     EISSN: None     Source Type: Journal    
DOI: 10.17221/5914-VETMED     Document Type: Review

References (51)

1. Affeld SH, Waegele S, Avila C, Kehraus, Koenig GM (2007): Distribution of homarine in some Opisthobranchia (Gastropoda: Mollusca). Bonner Zoologische Beitraege 55, 181-190
2. Alvarez P, Ferrari LF, Levine JD (2011): Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy. Annals of Neurology 70, 101-109
3. Ariza ME, Ramakrishnan R, Singh NP, Chauhan A, Nagarkatti PS, Nagarkatti M (2011): Bryostatin-1, a naturally occurring antineoplastic agent, Acts as a Toll-like receptor 4(TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. Journal of Biological Chemistry 286, 24-34
4. Chaves-Fonnegra A, Lopez-Victoria M, Parra-Velandia F, Zea S (2005): Chemical ecology of the excavating sponges Cliona aprica, C. caribbaea, C. delitrix and C. tenuis. Boletin de Investigaciones Marinas y Costeras 34, 43-67
5. Dahms HU, Gao QF, Hwang JS (2007): Optimized maintenance and larval production of the bryozoan Bugula neritina (Bugulidae: Gymnolaemata) in the laboratory. Aquaculture 265, 169-175
6. Davidson SK, Haygood MK (1999): Identification of sibling species of the bryozoan Bugula neritina that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont "Candidatus endobugula sertula". Biological Bulletin 196, 273-280
7. Davidson SK, Allen SW, Lim GE, Anderson CM, Haygood MG (2001): Evidence for the Biosynthesis of Bryostatins by the Bacterial Symbiont "Candidatus Endobugula sertula" of the Bryozoan Bugula neritina. Applied Environental Microbiology 67, 4531-4537
8. Debbab A, Aly AH, Proksch P (2011): Bioactive secondary metabolites from endophytes and associated marine derived fungi. Fungal Diversity 49, 1-12
9. Dunlap WC, Battershill CN, Liptrot CH, Coob RE, Bourne DG, Jaspars M, Long PF, Newman DJ (2007): Biomedicinals from the phytosymbionts of marine invertebrates: A molecular approach. Methods 42, 358-376
10. Ebada SS, Lin WH, Proksch P (2010): Bioactive sesterterpenes and triterpenes from marine sponges: occurrence and pharmacological significance. Marine Drugs 8, 313-346
11. Green AP, Lee ATL, Thomas EJ (2011): Total synthesis of a 20-deoxybryostatin. Chemical Communications 47, 7200-7202
12. Hale KJ, Manaviazar S (2010): New approaches to the total synthesis of the bryostatin antitumor macrolides. Chemistry-An Asian Journal 5, 704-754
13. Keck GE, Poudel YB, Cummins TJ, Rudra A, Covel JA (2011): Total synthesis of bryostatin 1. Journal of the American Chemical Society 133, 744-747
14. Kedei N, Telek A, Czap A, Lubart ES, Czifra G, Yang DZ, Chen JQ, Morrison T, Goldsmith PK, Lim LS, Mannan P, Garfield SH, Kraft MB, Li W, Keck GE, Blumberg PM (2011): The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCap human prostate cancer cell line. Biochemical Pharmacology 81, 1296-1308
15. Kubanek J, Whalen KE, Engel S, Kelly SR, Henkel TP, Fenical W, Pawlik JR (2002): Multiple defensive roles for triterpene glycosides from two Caribbean sponges. Oecologia (Berlin) 131, 125-136
16. Kuzirian AM, Epstein HT, Gagliardi CJ, Nelson TJ, Sakakibara M, Taylor C, Scioletti AB, Alkon DL (2006): Bryostatin enhancement of memory in Hermissenda. Biological Bulletin 210, 201-214
17. Laport MS, Santos OCS, Muricy G (2005): Marine sponges: potential sources of new antimicrobial drugs. Current Pharmaceutical Biotechnology 10, 86-105
18. Lopanik N, Lindquist N, Targett N, (2004a): Potent cytotoxins produced by a microbial symbiont protect host larvae from predation. Oecologia 139, 131-139
19. Lopanik N, Gufson KR, Lindquist N (2004b): Structure of bryostatin 20: A symbiont-produced chemical defense for larvae of the host bryozoan, Bugula neritina. Journal of Natural Products 67, 1412-1414
20. Lopanik N, Targett N, Linguist N (2006): Ontogeny of a symbiont-produced chemical defense in Bugula neritina (Bryozoa). Marine Ecology-Progress Series 327, 183-191
21. Lopez-Abarrategui C, Alba A, Lima LA, Maria-Neto S, Vasconcelos IM, Oliveira JTA, Dias SC, Otero-Gonzalez AJ, Franco OL (2012): Screening of antimicrobials from Caribbean Sea animals and isolation of bactericidal proteins from the littoral mollusk Cenchritis muricatus. Current Microbiology 64, 501-505
22. Lu Y, Woo SK, Krische MJ (2011): Total synthesis of bryostatin 7 via C-C bond-forming hydrogenation. Journal of the American Chemical Society 133, 13876-13879
23. Manaviazar S, Hale KJ (2011): Total synthesis of bryostatin 1: A short route. Angewandte-Chemie International Edition 50, 8786-8789
24. Manning TJ, Land M, Rhodes E, Chamberlin L, Rudloe J, Phillips D, Lam TT, Purcell J, Cooper HJ, Emmett MR, Marshall AG (2005): Identifying bryostatins and potential precursors from the Bugula neritina. Natural Product Research 19, 467-491
25. Manning TJ, Rhodes E, Land M, Parkman R, Sumner B, Lam TT, Marshall AG, Phillips D (2006): Impact of environmental conditions on the marine natural product bryostatin 1. Natural Product Research 20, 611-628
26. Mayer AMS, Gustafson KR (2008): Marine pharmacology in 2005-2006: Antitumour and cytotoxic compounds. European Journal of Cancer 44, 2357-2387
27. McGovern MT, Hellberg HE (2003): Cryptic species, cryptic endosymbionts, and geographical variation in chemical defences in the bryozoan Bugula neritina. Molecular Ecology 12, 1207-1215
28. Md SH, Fareed S, Ansari S, Khan MS (2012): Marine natural products: A lead for Anti-cancer. Indian Journal of Geo-Marine Sciences 41, 27-39
29. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, Nagarkatti P, Nagarkatti M, Chauhanet A (2010): Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS ONE 5, 11160
30. Mendla D (2003): Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: process developments and economics. Biomolecular Engineering 20, 441-458
31. Molinski TF, Dalisay DS, Lievens SL, Saludes JP (2009): Drug development from marine natural products. Nature Rewiew Drug Discovery 8, 69-85
32. Nakagawa-Goto K, Crimmins MT (2011a): Synthetic approaches to the bottom half fragment for bryostatin 11. Synlett 11, 1555-1558
33. Nakagawa-GotoK, Crimmins MT (2011b): Formal synthesis of the bryostatin northern Hemisphere: asymmetric synthesis of the B Ring and C1-C9 fragment. Synlett 11, 1413-1418
34. Odintsova NA, Usheva LN, Yakovlev KV, Kiselev KV (2011): Naturally occurring and artificially induced tumor-like formations in marine invertebrates: A search for permanent cell lines. Journal of Experimental Marine Biology and Ecology 407, 241-249
35. Park Y (2011): Mining invertebrate natural products for future therapeutic treasure. Natural Product Communications 6, 1403-1408
36. Paul VJ, Arthur K, Ritson-Williams R, Ross C, Kotty S (2007): Chemical defenses: From Compounds to Communities. Biological Bulletin 213, 226-251
37. Pawlik JR, Chanas B, Toonen RJ, Fenical W (1995): Defenses of Caribbean sponges against predatory reef fish. 1. Chemical Deterrency. Marine Ecology-Progress Series 127, 183-194
38. Pawlik JR, McFall G, Zea S (2002): Does the odor from sponges of the genus Ircinia protect them from fish predators? Journal of Chemical Ecology 28, 1103-1115
39. Pettit GR, Cichacz ZA, Gao F, Herold CL, Boyd MR (1993): Isolation and structure of the remarkable human cancer cell-growth inhibitors spongistatin-2 and spongistatin-3 from an eastern Indian ocean Spongia sp. Journal of the Chemical Society-Chemical Communications 14, 1166-1168
40. Prinsep MR, Yao B, Nicholson BK, Gordon DP (2004): The pterocellins, bioactive alkaloids from the marine bryozoan Pterocella vesiculosa. Phytochemistry Reviews 3, 325-331
41. Schmidt EW (2005): From chemical structure to environmental biosynthetic pathways: navigating marine invertebrate-bacteria associations. Trends in Biotechnology 23, 437-440
42. Sharp KH, Davidson SK, Haygood MG (2007): Localization of 'Candidatus Endobugula sertula' and the bryostatins throughout the life cycle of the bryozoan Bugula neritina. Isme Journal 1, 693-702
43. Sun MK, Alkon DL (2006): Bryostatin-1: Pharmacology and therapeutic potential as a CNS drug. CNS Drug Reviews 12, 1-8
44. Trindade-Silva AE, Lim-Fong GE, Sharp KH, Haygood MG (2010): Bryostatins: biological context and biotechnological prospects. Current Opinion in Biotechnology 21, 834-842
45. Wach JY, Gademann K (2012): Reduce to the maximum: truncated natural products as powerful modulators of biological processes. Synlett 163-170
46. Wender PA, Reuber J (2011): Function oriented synthesis: preparation and initial biological evaluation of new A-ring-modified bryologs. Tetrahedron 67, 9998-10005
47. Wender PA, Schrier AJ (2011): Total synthesis of bryostatin 9. Journal of the American Chemical Society 133, 9228-9231
48. Wender PA, Baryza JL, Brenner SE, DeChristopher BA, Loy BA, Schrier AJ, Verma VA (2011): Design, synthesis and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proceedings of the National Academy of Sciences of the United States of America 108, 6721-6726
49. Winston JE, Woollacott RM (2008): Redescription and revision of some red-pigmented Bugula species. Bulletin of the Museum of Comparative Zoology 159, 179-212
50. Zhu JB, Wan XY, Zhu YP, Ma XL, Zheng YW, Zhang TB (2010): Toxicity of bryostatin-1 on the embryo-fetal development of Sprague-Dawley Rats. Birth Defects Research part B-Developmental and Reproductive Toxicology 89, 171-174
51. Zohar O, Lavy R, Zi XM, Nelson TJ, Hongpaisan J, Pick CG, Alkon DL (2011): PKC activator therapeutic for mild traumatic brain injury in mice. Neurobilogy of Disease 41, 329-337